LASS2 enhances chemosensitivity to cisplatin by inhibiting PP2A-mediated β-catenin dephosphorylation in a subset of stem-like bladder cancer cells

The benefits of first-line, cisplatin-based chemotherapy for muscle-invasive bladder cancer are limited due to intrinsic or acquired resistance to cisplatin. Increasing evidence has revealed the implication of...

Source: BMC Medicine - January 9, 2024 Category: Internal Medicine Authors: Hongjin Shi, Zhiyong Tan, Bowen Duan, Chunming Guo, Chong Li, Ting Luan, Ning Li, Yinglong Huang, Shi Chen, Jixian Gao, Wei Feng, Haole Xu, Jiansong Wang, Shi Fu and Haifeng Wang Tags: Research article Source Type: research